Exudative age-related macular degeneration Eye Diseases
Conditions
Interventions
This is a 2-year, prospective, randomized, double-masked, controlled study of the safety and efficacy of repeated intravitreal injections of panitumumab combined with intravitreal injections of ranibi
Sponsors
Ufa Eye Research Institute
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Best corrected visual acuity of 300µm 3. Normal intraocular pressure 4. Transparent optical media 5. Absence of any other eye disease (except for cataract or pseudophakia) 6. No previous retinal or vitreoretinal surgery (except for peripheral retinal argon laser coagulation)
Exclusion criteria
Exclusion criteria: 1. Inability to attend the follow-up examinations 2. Inability to understand the purpose and structure of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Change in the retinal thickness in the foveola, as measured from Bruch´s membrane to the inner limiting membrane (i.e., including the retinal pigment epithelium layer), measured using optical coherence tomography (OCT) of the macula and optic nerve head at the time of the injections/re-injections 2. Best Corrected Visual Acuity (BCVA) measured using eye chart (ETDRS chart) at the time of the injections/re-injections | — |
Secondary
| Measure | Time frame |
|---|---|
| At baseline, at the time of the injections and re-injections, and at study end using optical coherence tomography: 1. Area and volume of subretinal tissue (differentiated between the compartment above and beneath the RPE line), and macular intraretinal and subretinal edema. 2. Size of atrophic lesions (geographic atrophies) | — |
Countries
Russian Federation
Contacts
Public ContactJost Jonas
Outcome results
None listed